Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): Interim results of a phase II trial.

被引：0
|
作者：
Sandhu, Shahneen Kaur
Violet, John A.
Ferdinandus, Justin
Thang, Sue-Ping
Iravani, Amir
Guo, Christina
Kong, Grace
Kumar, Aravind Ravi
Akhurst, Timothy J.
Beaulieu, Alexis
Murphy, Declan G.
Mooi, Jennifer
Tran, Ben
Toner, Guy C.
Williams, Scott
Hicks, Rodney J.
Hofman, Michael
机构：
[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Dept Radiat Oncol, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Ctr, Dept Canc Imaging, Melbourne, Vic, Australia
[4] Peter MacCallum Canc Ctr, Dept Canc Surg, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.5040
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5040
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Nephro- and hepatotoxicity after radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Becker, Anja
    Eppard, Elisabeth
    Kuerpig, Stefan
    Fisang, Christian
    Yordanova, Anna
    Essler, Markus
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [32] Exploratory covariate analysis for phase II clinical trial of sorafenib (S) in metastatic castrate-resistant prostate cancer (mCRPC)
    Jain, L.
    Aragon-Ching, J. B.
    Arlen, P. M.
    Gully, J. L.
    Venitz, J.
    Wright, J. J.
    Dahut, W. L.
    Figg, W. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
    Hadaschik, Boris
    Herrmann, Ken
    EUROPEAN UROLOGY, 2021, 80 (04) : 520 - 521
  • [34] Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
    Sartor, O.
    de Bono, J.
    Chi, K. N.
    Fizazi, K.
    Herrmann, K.
    Rahbar, K.
    Tagawa, S. T.
    Nordquist, L. T.
    Vaishampayan, N.
    El-Haddad, G.
    Park, C. H.
    Beer, T. M.
    Armour, A.
    Perez-Contreras, W. J.
    DeSilvio, M.
    Kpamegan, E.
    Gericke, G.
    Messmann, R. A.
    Morris, M. J.
    Krause, B. J.
    JOURNAL OF UROLOGY, 2022, 207 (02): : 467 - 468
  • [35] Tolerability and efficacy of chemotherapy in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial.
    Seruga, B.
    Horgan, A. M.
    Pond, G. R.
    Alibhai, S. M. H.
    Amir, E.
    De Wit, R.
    Eisenberger, M. A.
    Tannock, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] The Auckland experience with Lutetium-177 prostate-specific membrane antigen (177LU-PSMA-617) in advanced, metastatic castration-resistant prostate cancer (mCRPC): 2018-2020
    Hitchen, Nadia
    Waldron, Nick
    Lawrence, Nicola
    Fu, Simon
    Jacobs, Carmel
    Hanning, Fritha
    Lim, Remy
    Fong, Peter
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 67 - 67
  • [37] LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC)
    Sandhu, Shahneen
    Joshua, Anthony M.
    Emmett, Louise
    Crumbaker, Megan
    Bressel, Mathias
    Huynh, Rhonda
    Banks, Patricia Diana
    Wallace, Roslyn
    Hamid, Anis
    Inderjeeth, Andrisha Jade
    Tran, Ben
    Azad, Arun
    Alipour, Ramin
    Kong, Grace
    Kumar, Aravind Ravi
    Saghebi, Javad
    Williams, Scott
    Akhurst, Timothy J.
    Hicks, Rodney J.
    Hofman, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] Overall survival after177Lu-PSMA-617 molecular radiotherapy in patients with metastatic castrate-resistant prostate cancer: Post-hoc analysis of a prospective phase II trial
    Calais, J.
    Armstrong, W. R.
    Gartmann, J.
    Thin, P.
    Nguyen, K.
    Lok, V.
    Gosa, L.
    Slavik, R.
    Dalhbom, M.
    Herrmann, K.
    Eiber, M.
    Fendler, W. P.
    Czernin, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S488 - S488
  • [39] PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)
    Sandhu, S. K.
    Joshua, A. M.
    Emmett, L.
    Spain, L.
    Horvath, L. G.
    Crumbaker, M.
    Anton, A.
    Wallace, R.
    Pasam, A.
    Bressel, M.
    Cassidy, E.
    Banks, P.
    Kumar, A. R.
    Alipour, R.
    Akhurst, T.
    Kong, G.
    Davis, I. D.
    Williams, S.
    Hicks, R.
    Hofman, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S626 - S627
  • [40] Circulating androgen receptor (AR) gene amplification and resistance to 177Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of a phase II clinical trial.
    De Giorgi, Ugo
    Severi, Stefano
    Sarnelli, Anna
    Sansovini, Maddalena
    Monti, Manuela
    Gurioli, Giorgia
    Nicolini, Silvia
    Scarpi, Emanuela
    Casadei, Chiara
    Conteduca, Vincenza
    Matteucci, Federica
    Di Iorio, Valentina
    Amadori, Dino
    Paganelli, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345